atezolizumab

targets

all catalysts(41)

News(10)

• BioNTech faces 3rd mRNA setback as head and neck cancer therapy fails to improve survival
  While BNT113 failed to improve progression-free survival in patients with a type of head and neck cancer during a Phase 3 trial, BioNTech is holding out hope for an overall survival win—but analyst…
  biospace · 5d ago
• City Therapeutics targets $158M IPO; Iambic seeks $135M Nasdaq debut
  Plus news about Alchemist Capital, Newron Pharmaceuticals, Life Biosciences, Onyx Bio and Tecentriq. City Therapeutics charts $158M IPO: The RNAi startup from former Alnylam executives is looking t…
  endpoints · 9d ago
• Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
  A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.
  biopharma_dive · 11d ago
• Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
  MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate. The small-cell lung cancer trial hit its primary endpoint, although the B7-H3-directed ADC’s median overall survi…
  fiercebiotech · 1mo ago
• 5 drugmakers chasing Merck and Moderna in the cancer vaccine race
  Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…
  biospace · 1mo ago
• FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer
  The FDA has delayed its approval decision for Exelixis’ oral kinase inhibitor in combination with Roche’s Tecentriq for the treatment of metastatic colorectal cancer.
  fiercebiotech · 1mo ago
• BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
  BioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.
  fiercebiotech · 1mo ago
• The signal that changes everything: understanding MRD in oncology drug development
  Is the cancer truly gone?
  fiercebiotech · 1mo ago
• FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer
  In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, turning a contentious regulatory review into a landmark win that opens a new…
  fiercebiotech · 1mo ago
• BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
  Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would be discontinued for futility. The news follows Merck and Moderna’s Phase…
  biospace · 1mo ago